Article
Oncology
Yanjie Zhang, Hezhou Guo, Zhaoli Zhang, Wei Lu, Jiang Zhu, Jun Shi
Summary: This study revealed that interleukin-6 (IL-6) enhances lipid metabolism in skeletal muscle cells, thereby promoting chemoresistance in acute myeloid leukemia (AML). The mechanism involves IL-6-induced fatty acid (FA) uptake through stat3/CD36 pathway. Blocking CD36 can enhance the effect of chemotherapy drugs, representing a promising strategy for AML therapy.
EXPERIMENTAL CELL RESEARCH
(2022)
Article
Immunology
Uri Rozovski, Ivo Veletic, David M. Harris, Ping Li, Zhiming Liu, Preetesh Jain, Taghi Manshouri, Alessandra Ferrajoli, Jan A. Burger, Prithviraj Bose, Phillip A. Thompson, Nitin Jain, William G. Wierda, Srdan Verstovsek, Michael J. Keating, Zeev Estrov
Summary: This study suggests that CLL cells can produce high levels of PTX3, and phosphorylated STAT3 can transcriptionally activate the PTX3 gene. Inhibition of PTX3 may be beneficial for CLL patients.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Cell Biology
Nicole K. Nakamura, Darcy S. Tokunaga, Herena Y. Ha, Noemi Polgar
Summary: In obesity, chronic localization of CD36 translocase enhances FFA uptake and lipid accumulation in cells, leading to insulin resistance. This study reveals the importance of the exocyst complex in CD36 membrane trafficking and FFA uptake in muscle cells.
Article
Chemistry, Multidisciplinary
Zijuan Wu, Xiaoling Zuo, Wei Zhang, Yongle Li, Renfu Gui, Jiayan Leng, Haorui Shen, Bihui Pan, Lei Fan, Jianyong Li, Hui Jin
Summary: This study explores the role of N6-methyladenosine (m6A) modification and circular RNAs (circRNAs) in chronic lymphocytic leukemia (CLL). It establishes an m6A scoring system and an m6A-related circRNA prognostic signature, and identifies circTET2 as a potential prognostic biomarker for CLL. The findings demonstrate the importance of circTET2 in lipid metabolism and cell proliferation in CLL cells. The study also provides insights into the splicing process and RNA-binding proteins (RBPs) involved in the biogenesis of circTET2. Furthermore, the study shows the synergistic effects of mTOR inhibitor and FAO inhibitor on CLL cells. These findings have clinical significance in predicting prognosis and targeting treatment for CLL.
Article
Hematology
Lauren A. Thurgood, Oliver G. Best, Ashley Rowland, Karen M. Lower, Doug A. Brooks, Bryone J. Kuss
Summary: Many cancers, including chronic lymphocytic leukaemia (CLL), show low glucose uptake and high uptake of medium- and long-chain fatty acids (FAs). The differential FA uptake is observed in CLL patients with different immunoglobulin heavy variable chain usage (IGHV). Inhibition of FA uptake reduces the proliferation and viability of CLL cells, suggesting a potential therapeutic approach.
EXPERIMENTAL HEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Kristan V. Piroeva, Charlotte Mcdonald, Charalampos Xanthopoulos, Chelsea Fox, Christopher T. Clarkson, Jan-Philipp Mallm, Yevhen Vainshtein, Luminita Ruje, Lara C. Klett, Stephan Stilgenbauer, Daniel Mertens, Efterpi Kostareli, Karsten Rippe, Vladimir B. Teif
Summary: This study compared the nucleosome positions in chronic lymphocytic leukemia (CLL) patients and healthy individuals, and found significant changes in nucleosome positioning in CLL. The spacing between nucleosomes was shortened, and changes in nucleosome occupancy were linked to chromatin remodeling and reduced DNA methylation. Nucleosome positioning can be used to classify CLL subtypes and monitor disease progression.
Article
Biochemistry & Molecular Biology
Nannan Pang, Xierenguli Alimu, Rong Chen, Maliya Muhashi, Jiajia Ma, Gang Chen, Fang Zhao, Lei Wang, Jianhua Qu, Jianbing Ding
Summary: This study revealed that Tim-3 was overexpressed in CLL patients, along with elevated levels of Galectin-9/Tim-3 signaling pathway, which were associated with disease progression. By negatively regulating CD4(+) T cells, the activated Galectin-9/Tim-3 pathway suppressed Th1 effector function and promoted Treg cells to participate in immune escape of CLL. These findings suggest that this pathway could be a potential target for immunotherapy in CLL patients.
Article
Nutrition & Dietetics
Won-Shik Choi, Xia Xu, Susan Goruk, Yixiong Wang, Samir Patel, Michael Chow, Catherine J. Field, Roseline Godbout
Summary: GBM neural stem-like cells express high levels of FABP7, and increasing DHA content can reduce their migration ability, potentially offering therapeutic value.
Article
Medicine, General & Internal
Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fuerstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindstrom, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Bjoern Schoettker, Thomas Noesslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jaeger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brueggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek
Summary: In fit patients with CLL, venetoclax-obinutuzumab, with or without ibrutinib, showed superior results compared to chemoimmunotherapy as a first-line treatment, with higher rates of undetectable minimal residual disease and progression-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer
Summary: Telomeres play a crucial role in chronic lymphocytic leukemia (CLL), with their dysfunction shaping the disease progression. Members of the shelterin complex and TERT activation are closely associated with CLL cell survival and proliferation.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Freda K. Stevenson, Francesco Forconi, Thomas J. Kipps
Summary: Research into chronic lymphocytic leukemia has led to significant improvements in the assessment and treatment of patients, with designer drugs now successfully targeting tumor cells based on their biology. Classifying CLL into unmutated (U) and mutated (M) diseases based on the mutational status of IGHV sequences reveals distinct origins, biology, and clinical behaviors for each. Despite advances, challenges such as cell-escape strategies and immunosuppression remain, necessitating continued research into CLL biology.
Article
Hematology
Fabienne Meier-Abt, Junyan Lu, Ester Cannizzaro, Marcel F. Pohly, Sandra Kummer, Sibylle Pfammatter, Laura Kunz, Ben C. Collins, Ferran Nadeu, Kwang Seok Lee, Peng Xue, Myriam Gwerder, Michael Roiss, Jennifer Huellein, Sebastian Scheinost, Sascha Dietrich, Elias Campo, Wolfgang Huber, Ruedi Aebersold, Thorsten Zenz
Summary: This study uncovered mutations affecting protein expression in CLL and identified signaling pathways associated with trisomy 12. STAT2 protein expression was linked to specific drug responses, providing a protein expression reference map for CLL.
Article
Oncology
David Allard, Pavel Chrobak, Yacine Bareche, Bertrand Allard, Priscilla Tessier, Marjorie A. Bergeron, Nathalie A. Johnson, John Stagg
Summary: Our study identified CD73 as a pro-leukemic immune checkpoint in CLL and uncovered a previously unknown sex bias for the CD73-adenosine pathway. The therapeutic potential of targeting CD73 in CLL was investigated using genetically engineered mice, revealing a pro-leukemic role for CD73 in an autochthonous mouse model of CLL. Our findings suggest that targeting CD73 in CLL in combination with anti-PD-1/PD-L1 immunotherapies may be beneficial, with sex potentially contributing to responses to adenosine-targeting agents.
Review
Oncology
Chengwei Ruan, Yankai Meng, Hu Song
Summary: CD36 is upregulated in various cancer types and associated with poor clinical outcomes and adverse clinicopathological features. It regulates tumor growth, metastasis, and drug resistance through diverse molecular mechanisms. CD36 plays a crucial role in tumor metabolism and could be a potential therapeutic target.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Review
Oncology
Yu Nie, Xiaoya Yun, Ya Zhang, Xin Wang
Summary: Metabolic reprogramming plays a vital role in the initiation and progression of chronic lymphocytic leukemia (CLL). This review summarizes the critical metabolic processes in CLL and discusses the regulation of metabolism by cells in the microenvironment and oncogenes/tumor suppressor regulators. Targeting metabolic enzymes or signal pathways may impede the progression of CLL.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
